Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. by Graham, C et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 5 | May 2001 501
Examination of the Melatonin Hypothesis in Women Exposed at Night to
EMF or Bright Light
Charles Graham, Mary R. Cook, Mary M. Gerkovich, and Antonio Sastre
Midwest Research Institute, Kansas City, Missouri, USA
Breast cancer is the most common cause of
cancer morbidity and mortality in women.
For unknown reasons, incidence rates con-
tinue to rise and to exhibit signiﬁcant varia-
tion across international boundaries (1–4).
Risks are highest in North America and
northern Europe and lowest in Asia and
Africa (2). This pattern has led to the view
that environmental factors associated with
industrialization and urbanization may be
involved in the etiology of this disease (5).
Stevens (3) noted that a key characteristic of
modern industrial society is the increased use
of electric power, with its associated expo-
sure to power-frequency electric and mag-
netic ﬁelds (EMF) and the presence of high
levels of light at night (LAN). Stevens pro-
posed, and later reﬁned (3,6), a biologically
based explanation of how increased exposure
to EMF and/or LAN might increase the risk
for hormone-sensitive cancers, particularly
breast cancer. Now widely known as the
melatonin hypothesis, it has continued to
capture the attention of researchers because
its focus on a single hormone promises a
parsimonious explanation for a health prob-
lem of great public concern. 
Melatonin is the chief secretory product
of the pineal gland. It exhibits a marked circa-
dian rhythmicity in all species studied, includ-
ing humans, with circulating levels being high
at night and low during the daylight hours.
Because of it capability to signal daily and sea-
sonal changes in the light/dark cycle, it is best
known as the primary regulator of reproduc-
tive physiology in seasonally breeding species
(7). Melatonin synchronizes the ebb and ﬂow
of reproductive hormones such as estrogen so
that mating and birth in these species occur at
times that are optimal for survival. According
to the melatonin hypothesis, environmental
factors that reduce melatonin increase breast
cancer risk in humans because the reduction
of melatonin allows circulating levels of estro-
gen to rise. This rise, in turn, stimulates the
turnover of breast epithelial stem cells and
increases the risk for malignant transforma-
tion. Thus, this line of reasoning holds that
melatonin acts indirectly on cancer risk by
modulating the secretion of hormones impli-
cated in carcinogenesis. 
Melatonin is reported to block the estro-
gen-induced proliferation of human breast
cancer cells in vitro and to suppress mam-
mary tumorigenesis in rats (8). Of 71 small-
animal exposure studies recently reviewed by
Brainard et al. (4), 48 studies report that
EMF exposure is associated with alterations
in important aspects of melatonin biosynthe-
sis, secretion, or metabolism. The literature
on exposure of small animals is mixed, how-
ever, with numerous instances of inconsistent
findings and failures to replicate findings,
both within and between laboratories.
Nighttime plasma melatonin levels are also
reported to be lower in women with estro-
gen-receptor positive breast cancer compared
to healthy women (9), and in women with
primary breast cancer compared to women
with benign breast disease (10). These
reported differences, however, often disap-
pear under more controlled conditions (11).
It is also difficult to assess the meaning of
these ﬁndings in clinical patients due to the
presence of disease and its possible effect on
melatonin levels (12).
In contrast to the results with small ani-
mals, controlled studies with large animals
(sheep, baboons, and humans) have reported
uniformly negative results (13–16). For exam-
ple, no effects on melatonin or its major uri-
nary metabolite, 6-hydroxymelatonin-sulfate
(6-OHMS), were found in human exposure
studies that varied such key magnetic field
parameters as frequency (50 Hz or 60 Hz),
intensity [1–127.3 microTesla (µT)], dura-
tion (1–4 consecutive nights), polarity (linear
or circular polarization), and exposure pattern
(continuous or intermittent) (17–22). Why
are exposure effects evident in small but not
large animals? Brainard et al. (4) suggested
various possibilities: testing of nocturnal ver-
sus diurnal and seasonally versus nonseason-
ally breeding species; substantial species
differences in the anatomical location, cellular
structure, and morphology, of the pineal
gland itself; marked variation in the quantity,
substructure, and homogeneity of the tissues
actually exposed to the magnetic field; and
the present uncertainty regarding the actual
locus of action of the magnetic ﬁeld.
Whether reduced melatonin levels pre-
dispose individuals to increased risk of can-
cer is unknown. Published reports have
evaluated the effects of EMF exposure on
melatonin, but not on the cascading
sequence of changes in melatonin and estro-
gen proposed to occur in women. It is also
important to note that almost all of the
above human exposure studies were per-
formed on healthy young men. Thus, little is
known about EMF exposure effects on
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It has been hypothesized that the increased incidence of breast cancer in industrial societies is
related to greater exposure to power-frequency electric and magnetic ﬁelds (EMF) and/or the pres-
ence of high levels of light at night (LAN). EMF and LAN are said to reduce circulating levels of
the hormone melatonin which, in turn, allows estrogen levels to rise and stimulate the turnover of
breast epithelial stem cells and increase the risk for malignant transformation. Three laboratory-
based studies, in which a total of 53 healthy young women were exposed at night to EMF or to
LAN under controlled exposure conditions, were performed to determine whether such exposures
reduce melatonin and are associated with further alterations in estrogen. All-night exposure to
industrial-strength magnetic ﬁelds (60 Hz, 28.3 µT) had no effect on the blood levels of melatonin
or estradiol. In contrast, nocturnal melatonin levels were profoundly suppressed, and the time of
peak concentration was signiﬁcantly delayed in women exposed to LAN, regardless of whether they
were in the follicular or luteal phase of the menstrual cycle. These changes, however, were not asso-
ciated with alterations in point-for-point matching measures of estradiol. Women who chronically
secrete high or low amounts of melatonin each night (area-under-curve range: 86–1,296 pg/mL)
also did not differ in their blood levels of estradiol. Taken together, these results are consistent
with a growing body of evidence which generally suggests that environmental EMF exposure has
little or no effect on the parameters measured in this report. Key words: breast cancer, electromag-
netic fields, estrogen levels, light at night, melatonin, neuroendocrine, reproductive hormones,
women’s health. Environ Health Perspect 109:501–507 (2001). [Online 9 May 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p501-507graham/abstract.htmlwomen or about how such effects might be
inﬂuenced by the large changes that naturally
occur in estrogen as a function of the men-
strual cycle. Finally, there are no studies in
women of the relationship between LAN and
the sequence of hormonal events described in
the melatonin hypothesis, or between LAN
and breast cancer. In this report, we address
two key issues: first, whether exposure to
EMF or LAN reduces nocturnal levels of
melatonin in women, and second, whether
these reductions are associated with alter-
ations in blood levels of estrogen. 
Materials and Methods
Common procedures. The effects of noctur-
nal exposure to EMF on melatonin and estra-
diol were evaluated in two studies; exposure
to LAN was assessed separately in a third
study. Some methods and procedures were
common across studies and are described
here. In each study, the test protocol received
prior review and approval by the Institutional
Review Board at the Midwest Research
Institute (MRI), and we obtained written
informed consent from each volunteer before
her participation in a study. All volunteers
met the following eligibility criteria for study
participation: regular sleep/dietary habits, no
evening/night work, no medications particu-
larly hormonal birth control, not pregnant,
and regular (26–32 days) and predictable
(≤ 2 days) menstrual cycles. All studies were
performed using a crossover experimental
design in which subjects were assigned ran-
domly to conditions and served as their own
controls. The two EMF exposure studies
were performed double-blind. All partici-
pants refrained from consuming alcohol for
24 hr before a test session, and had no caf-
feine after 1700 hr on the day of a session. 
EMF exposure facility. The two EMF
exposure studies were performed in the
magnetic field exposure test facilities at the
MRI. Exposure characteristics have been
documented by the U.S. Department of
Energy (23) as part of the U.S. National
Electric and Magnetic Field Research and
Public Information Dissemination program
directed by the National Institute of
Environmental Health Sciences (NIEHS)
(16). The facilities have been described by
Cohen et al. (24) and by Doynov et al. (25).
In the control condition of each EMF study,
the women were exposed overnight to the
ambient 60-Hz background magnetic field
measured in the laboratory (≤ 0.2 µT). This
intensity is characteristic of residential expo-
sures. In the test condition for each study,
subjects were exposed to a circularly polar-
ized, 60-Hz sinusoidal magnetic ﬁeld gener-
ated at a resultant flux density of 28.3 µT.
This intensity is within the range of
exposures associated with electric utility
operations and the use of industrial machin-
ery or power equipment. 
Each volunteer slept on a bed oriented
north–south in a sound-attenuated and air-
conditioned exposure test room (a cube
approximately 2.4 m on each side). The ﬁeld-
generation coils were located out of sight
behind the walls, ceiling, and floor of the
exposure room. The horizontal axis of the
ﬁeld was oriented north–south, and the ver-
tical axis was perpendicular to the ﬂoor. To
produce the circularly polarized field, one
axis of the field was phase-shifted 90° with
respect to the other axis. Magnetic ﬁeld gen-
eration at the selected frequency, intensity,
waveform, pattern, and duration was con-
trolled by software operating in conjunction
with power generation systems. 
The subjects were exposed to the gener-
ated magnetic field using the intermittent
exposure protocol described by Graham et al.
(18). This consisted of alternating 1-hr ﬁeld-
on and field-off periods. During field-off
hours, the coils were not energized. During
ﬁeld-on hours, the ﬁeld cycled on and off at
15-sec intervals. A zero-current crossing tech-
nique allowed the magnetic fields to be
switched without introducing artifacts
because of the generation of high-frequency
magnetic ﬁeld transients at the switch points.
The decision to emphasize intermittent expo-
sure and circular polarization was based on
research indicating that such exposure is asso-
ciated with alterations in human physiology
(26–28), and also on rodent research report-
ing that circularly polarized fields are more
effective than linearly polarized fields in
reducing nocturnal melatonin levels (29). 
Measures. Melatonin was assayed using
the Bühlmann radioimmunoassay (RIA) dis-
tributed by ALPCO, Ltd. (Windham, NH).
The detection limit for this assay is 0.3
pg/mL. The inter- and intra-assay coeffi-
cients of variation (CVs) are routinely below
10% throughout the assay range (30,31).
First-void morning urine samples were
assayed for the melatonin metabolite (6-
OHMS) by RIA (Stockgrand, Guildford,
Surrey, UK). The lower limit of quantitation
for this RIA is 3.1 pg/mL, and the inter- and
intra-assay CVs are routinely below 10% in
our laboratory (30,31). Unlike melatonin,
which is an uncharged compound that read-
ily passes through and equilibrates across
plasma and tissue membranes, 6-OHMS is a
charged metabolite that appears in urine by
ﬁltration. Thus, the volume of urine an indi-
vidual produces can influence the values
obtained for 6-OHMS. To correct for this,
urinary creatinine was also assayed using a
COBAS MIRA chemistry analyzer (Roche,
Montclair, NJ; kinetic Jaffe reaction). The 6-
OHMS results were normalized to creatinine
concentration and expressed as nanograms
6-OHMS per milligram creatinine. We mea-
sured estradiol using a double-antibody 125I
RIA (Diagnostic Products Corporation, Los
Angeles, CA). The sensitivity of this assay is
5 pg/mL, and the inter- and intra-assay CVs
were each below 10%. 
Study 1 
The 22 healthy women volunteers (mean age
24 years, range 19–35 years) in this study
came to the laboratory for two test sessions
spaced about a month apart. For each indi-
vidual, the test sessions occurred at the same
time point in the menstrual cycle between
days 3–8 after the onset of menstruation.
We restricted testing to this period because it
is a time of relative hormonal stability, and
this enhanced our capability to detect even
small field-related changes, should they
occur. In one session, the women were
exposed all night (2300–0700 hr) to the
generated 60-Hz magnetic ﬁelds. The other
session was a control condition similar in all
respects, except that it did not involve expo-
sure to the magnetic ﬁelds. Half of the study
group first participated in the control ses-
sion, and the remaining subjects participated
in the reverse order. 
Procedures. On arrival at the laboratory,
the volunteers changed into sleepwear and the
study nurse inserted an indwelling butterﬂy
catheter into a vein in the arm or back of the
hand to minimize disturbance during the sub-
sequent collection of hourly blood samples.
After the subject got into bed in the exposure
test room, the ﬁrst blood sample was obtained
from the subject at 2255 hr. The automated,
double-blind/field-control system was acti-
vated, and subjects remained in bed until
0700 hr. During the night, the laboratory was
darkened and ambient lighting in the expo-
sure room was maintained at less than 10 lux
(lx), a level known not to interfere with
human melatonin secretion (32). The nurse
entered the exposure room each hour on the
hour to collect blood samples. These were
drawn from the catheter into EDTA vacu-
tainer tubes, centrifuged, and aliquots of the
extracted plasma were frozen at –20°C for
later assay of melatonin and estradiol. 
If a subject needed to use the bathroom
during the night, we were concerned that the
attendant light exposure might inhibit noc-
turnal melatonin secretion. Light-induced
inhibition of melatonin is both intensity
dependent and spectrally sensitive, with
green light being most effective and red light
almost completely ineffective (33). We
simultaneously controlled for both of these
factors by asking subjects to wear fluoro-
scopic goggles equipped with red lenses
(Model 502300, Cone Instruments, Solon,
Ohio) if they needed to get up during the
night. The goggles allowed night vision to be
Articles • Graham et al.
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topic transmittance of the incident light, and
limiting it to the red portion of the visible
light spectrum. 
We used analysis of variance (ANOVA)
as the primary statistical technique to test for
differences in melatonin and estradiol
between exposure and control conditions.
Analysis variables included the two orders of
testing, control versus exposure test condi-
tions, and the hourly blood values for the
outcome measures. Probability values were
corrected for lack of sphericity using the
Huynh-Feldt epsilon technique. Statistical
signiﬁcance was set at p ≤ 0.05. 
Results. Melatonin. Figure 1 plots hourly
mean values for plasma melatonin in the
control and magnetic ﬁeld exposure test con-
ditions. The typical nocturnal secretion
curve was observed in both conditions.
Melatonin levels rapidly increased in the
early portion of the night, peaked between
0200 and 0400 hr, and then slowly declined
as morning approached. Although these
changes across the night were highly signiﬁ-
cant (F7,140 = 23.72, p = 0.0001), ANOVA
indicated that exposure to the magnetic ﬁeld
had no effect on the melatonin secretion
curve. As clearly illustrated in Figure 1, mag-
netic field exposure did not alter the area
under the curve (AUC), the timing or
amplitude of the melatonin peak, the slope
of the increase in melatonin between mid-
night and the peak, or the slope of the
decrease from the peak to 0700 hr. 
Estradiol. Estradiol does not have a circa-
dian-type nocturnal secretion curve. Thus, we
measured plasma concentrations of estradiol
at the start of the control or exposure session
(2300 hr), at the approximate time when
melatonin reached it peak concentration in
the circulation (0300 hr), and at the end of a
session (0700 hr). ANOVA performed on
these data over all 22 subjects did not
reveal any exposure-related differences in
estradiol compared to control conditions.
Interpretation of this result, however, was
complicated by the fact that estradiol levels
for a number of subjects were different in
their first session compared to their second
session, regardless of the type of exposure the
subjects had received. In a preliminary exam-
ination of this issue, we deleted the ﬁve sub-
jects who showed the greatest differences in
estradiol between sessions and performed the
analysis again on the remaining 17 subjects.
This analysis revealed a signiﬁcant exposure
effect (F2,32 = 5.67, p = 0.012). Women had
higher mean blood levels of estradiol when
exposed to the magnetic field compared to
control conditions (24.2 vs. 18.2 pg/mL,
respectively). This effect was spurious, how-
ever, as indicated by the fact that the differ-
ence in estradiol levels was apparent at 2300
hr before magnetic field exposure began.
Given the excessive intersession variability
we observed under the present experimental
design, we had little confidence in these
results for estradiol. We therefore decided to
change the design to reduce the variability in
estradiol and to repeat the study with a new
group of women. 
Study 2
This study followed the design of study 1,
with one major exception. To reduce the
variability in estradiol measures, we sched-
uled the counterbalanced control and expo-
sure test sessions for 2 consecutive nights
between days 3 and 8 of each individual’s
menstrual cycle, rather than 1 month apart as
in the earlier study. We also measured blood
levels of melatonin and estradiol every hour
from 2300 hr to 0700 hr to provide a point-
by-point match. In addition, the subjects
were asked to provide first-void morning
urine samples after each nocturnal test ses-
sion (these included all urine voided after
2300 hr) to determine if magnetic ﬁeld expo-
sure altered 6-OHMS, the major urinary
metabolite of melatonin. Fifteen women vol-
unteers (mean age 20 years, range 18–24
years) participated in study 2. 
Results. Melatonin and 6-OHMS. Figure
2 plots the hourly mean values for melatonin
in the control and exposure test conditions.
As in the earlier study, the nocturnal secretion
curve for melatonin was similar in both con-
ditions. Statistical analysis by ANOVA did
not reveal any difference in plasma measures
of melatonin secretion as a function of expo-
sure to the magnetic field compared to the
control condition (F7,91 = 1.43, p = 0.22).
Magnetic ﬁeld exposure also had no effect on
the urinary measure of melatonin metabo-
lism. 6-OHMS levels in first-void morning
urine were essentially the same in control and
exposure conditions (mean ± SE = 31.1 ± 4.1
and 31.6 ± 4.2 ng/mg/creatinine, respec-
tively). As expected, the Pearson correlation
(r) between the AUC for plasma melatonin
and the creatinine-corrected 6-OHMS values
was positive, statistically signiﬁcant, and not
differentially altered by magnetic ﬁeld expo-
sure ( r = 0.70, p = 0.004, 48% of variance),
compared to control conditions (r = 0.73, p =
0.002, 53% of variance). 
Estradiol and melatonin. The change in
experimental design had the desired effect of
reducing session-to-session variance in estra-
diol measures. The Pearson correlation
between the AUC for estradiol in sessions 1
and 2 was signiﬁcant ( r = 0.727, p < 0.002,
53% of variance), as was the correlation
between the initial values obtained for
estradiol at the start (2300 hr) of each ses-
sion (r = 0.83, p < 0.003, 69% of variance).
The AUC values obtained for estradiol in
the control and exposure sessions were also
Articles • EMF effects on melatonin and estradiol
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Figure 1. Melatonin (mean ± SE) was not reduced
in 22 women by all-night magnetic field (60 Hz,
28.3 µT) exposure compared to equivalent no-
exposure (0.2 µT) control conditions (study 1).
Figure 2. Melatonin (mean ± SE) was not reduced
in 15 women by all-night magnetic field (60 Hz,
28.3 µT) exposure compared to equivalent no-
exposure (0.2 µT) control conditions (study 2).
Figure 3. Estradiol (mean ± SE) did not increase
in 15 women during all-night magnetic field (60
Hz, 28.3 µT) exposure compared to equivalent no-
exposure (0.2 µT) control conditions (study 2).
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0.2 µ Tsimilar (114.72 and 114.56 pg/mL, respec-
tively). Figure 3 plots hourly mean blood
levels of estradiol to illustrate the nocturnal
secretion pattern of this hormone in the con-
trol and exposure test sessions. The pattern is
essentially flat across the night, with mean
values ﬂuctuating within a limited range (~2
pg/mL). Thus, although blood levels of
melatonin changed significantly across the
night regardless of exposure (Figure 2; F7,91
= 9.2, p = 0.001), neither these circadian-
type changes nor exposure to the magnetic
ﬁeld had any apparent inﬂuence on the noc-
turnal secretion pattern of estradiol. 
Study 3
Exposure to the magnetic ﬁeld in the above
two studies did not result in a reduction of
melatonin. Thus, the studies did not allow
us to address our second key issue of interest;
namely, whether reductions in melatonin are
followed by alteration in estrogen, and
whether any effects found differ as a func-
tion of time in the menstrual cycle. In this
study, we used the known suppressive effects
of exposure to bright light at night to cause a
profound reduction in the total amount of
melatonin secreted over the night, and also
to shift (by hours) the time when melatonin
normally reaches peak concentration in the
circulation. The study participants included
women in the luteal as well as the follicular
phase of their menstrual cycle. 
The study group consisted of 16 healthy
women volunteers (mean age 22 years,
range 19–26 years). The women came to
the laboratory on two consecutive nights
(2030–0700 hr). Half of the subjects were
tested between days 3 and 8 of their men-
strual cycle (follicular group). The remain-
ing subjects were tested between days 18
and 23 of their menstrual cycle (luteal
group). Within each group, half of the sub-
jects were exposed to bright light on their
first night in the laboratory, followed by
exposure to dim light on the second night.
The remaining subjects participated in the
reverse order.
Procedures. The women were scheduled
in groups of two and arrived at the laboratory
at 2030 hr. They changed into sleepwear, and
the study nurse inserted an indwelling butter-
ﬂy catheter into a vein in the arm or back of
the hand for the collection of blood samples
each hour on the hour from 2100 hr to 0700
hr. For the ﬁrst 4 hr (2100–0100 hr), the sub-
jects sat in comfortable chairs at a table posi-
tioned in the center of the light exposure
room (6.1 m × 6.1 m × 2.75 m). They
watched movies displayed on a combination
television/videocassette recorder (TV/VCR)
located in front of them, and were monitored
to assure they did not fall asleep or close their
eyes for extended periods of time. 
In the dim-light control condition, the
women wore the fluoroscopic goggles
described earlier. We switched on the ceiling
ﬂourescent lighting ﬁxtures, which produced
a measured (Digital Light Meter, Model LX-
101; Edmonds Scientific Co., Barrington,
NJ) illuminance level of 575 lx on the table
top in front of the subjects. When viewed
through the goggles, however, the illumi-
nance level was reduced to 25 lx. The
subjects did not wear the goggles in the
bright-light exposure condition. In that
condition, we switched on the ceiling lights
as well as an additional six banks of ﬂuores-
cent lighting, each containing eight SYLVA-
NIA cool-white, 48-inch, 40-watt tubes
(OSRAM SYLVANIA, Danvers, MA).
Track lighting attached to the ceiling around
the room was also turned on. This arrange-
ment produced a bright, evenly lit area in
which subjects were able to watch the
TV/VCR screen for the 4-hr exposure
period without reported eye strain. The illu-
minance level in the bright-light test condi-
tion was 5,200 lx at the measurement
location on the table top in front of the sub-
jects. Light exposure ended at 0100 hr, and
the subjects went to sleep for the remainder
of the night in the magnetic field exposure
test rooms described earlier. The ﬁeld gener-
ators were not switched on, however, and
the subjects were not exposed to the mag-
netic ﬁelds used earlier. The laboratory was
darkened at night, and ambient lighting in
the sleeping rooms was maintained at < 10
lx. Blood samples were collected each hour
and the subjects awakened at 0700 hr the
next morning. 
Results
Figure 4 illustrates the effect of light expo-
sure on melatonin. Hourly mean values
from  2100 hr to 0700 hr are plotted for the
follicular and luteal groups under bright-
and dim-light test conditions. Exposure to
the bright light significantly reduced the
total amount (AUC) of melatonin the
women secreted over the entire night (F1,14
= 41.99; p < 0.0001). This effect was not
different in the follicular and luteal phases of
the menstrual cycle (reductions in AUC of
39% and 35%, respectively). An even more
profound reduction of melatonin was
observed during the initial 4-hr light expo-
sure period. Exposure to the bright light
from 2100 hr to 0100 hr reduced melatonin
secretion by more than 90%, compared to
the dim-light control condition over the
same time period. Further examination indi-
cated that exposure to the bright light also
caused a significant delay in the time when
melatonin reached peak concentration in the
circulation. Mean blood levels of melatonin
peaked at 0100 hr in the dim-light control
sessions. Peak concentrations of melatonin
occurred at 0500 hr in the bright-light expo-
sure condition, a delay of 4 hr. This figure
illustrates two important aspects of the data.
First, the rise and fall of melatonin under
dim-light control conditions, as well as the
response of this hormone to the suppressive
effects of bright light, are essentially identical
in the early and late phases of the menstrual
cycle. Second, once the suppressive effects of
bright light are removed, blood levels of
melatonin in both menstrual phases recover
and peak at the same level observed for sub-
jects unexposed to light, illustrating the
power of the endogenous circadian rhythms
that control this hormone. The slope of the
increase after bright-light exposure is not dif-
ferent from the slope of the increase seen at
the start of the dim-light control condition
in either group. 
As shown in Figure 5, the marked
changes observed in melatonin were not
associated with any apparent alteration in
point-by-point, matching hourly mean
blood levels of estradiol. AUC measures for
estradiol were not different in bright- versus
dim-light exposure sessions (F1,13 = 0.08, p =
0.78). Phase of the menstrual cycle was the
single factor found to inﬂuence estradiol. As
expected, mean blood levels of estradiol were
lower in the follicular group compared to the
luteal group (26 vs. 62 pg/mL, F1,13 = 8.17,
p = 0.01), as was the AUC (F1,13 = 5.20, p =
0.04). 
We performed one additional analysis
using the combined data from the above three
studies. The present studies examined the
effects of acute exposure to EMF and LAN on
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Figure 4. Mean (± SE) melatonin levels are plotted
from 2100 hr to 0700 hr for eight women in the fol-
licular menstrual phase (days 3–8) initially
exposed for 4 hr to bright (5,200 lx) light or to dim
(25 lx) light (study 3). Similar data are shown for
eight women in the luteal phase (days 18–23)
exposed to the same bright and dim light condi-
tions. Bright light reduced the total amount of
melatonin secreted (p < 0.0001) and delayed peak
blood concentrations by 4 hr. 
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25 lx, lutealmelatonin and estradiol. It has been known
for some time, however, that there are large
differences between individuals in the amount
of melatonin they chronically secrete each
night (7). For example, in previous research
on a sample of more than 250 volunteers, we
found that AUC values over the night ranged
from 62 to 854 pg/mL (30,31). In view of the
relationships proposed by the melatonin
hypothesis, we were curious whether blood
levels of estradiol might also naturally differ in
women with chronically high versus low daily
secretions of melatonin. 
Of the 53 women who participated in
the above studies, 44 women could provide
the complete set of data needed to perform
this analysis. All of these women were in the
follicular phase of the menstrual cycle during
their participation. Their melatonin levels
had been measured each hour from 2300 hr
to 0700 hr in the no-exposure control condi-
tion of the two magnetic-ﬁeld exposure stud-
ies or in the dim-light control condition of
the LAN study. Estradiol levels had also been
measured in these individuals at three com-
mon time points across studies (2300, 0300,
and 0700 hr) under the same control condi-
tions. The mean level of estradiol was com-
puted for each women using the data
collected at these three time points. We con-
sidered this measure to be a good representa-
tion of the total nocturnal output of estradiol
for an individual because it correlated highly
with the AUC measures of estradiol calcu-
lated over the full night in studies 2 and 3 (r
= 0.934, p < 0.00001, 87% of variance
accounted for). We performed regression
analysis to examine the relationship between
each woman’s mean estradiol level (range:
4–60 pg/mL) and her melatonin AUC calcu-
lated over the entire night (range: 86–1296
pg/mL). There was no relationship between
estradiol and melatonin in this data set (r =
0.058, p = 0.71, < 0.01% of the variance
accounted for). 
Discussion 
Our results indicate that acute, all-night
exposure to industrial-strength, power-fre-
quency magnetic ﬁelds has no effect on the
nocturnal secretion patterns of melatonin
and estradiol in healthy, young women
tested in the follicular phase of the menstrual
cycle. These results are consistent with the
negative findings in regard to melatonin
obtained in earlier research performed with
healthy, young men exposed under similar
magnetic ﬁeld test conditions (18–22,34). In
contrast, when the women volunteers were
exposed to bright light at night, nocturnal
melatonin levels were profoundly suppressed
and the time when melatonin reached its
peak concentration in the blood was signiﬁ-
cantly delayed. These changes in melatonin
were equivalent for women in the follicular
and the luteal phases of the menstrual cycle.
The signiﬁcant light-induced suppression of
melatonin, however, was not accompanied
by any change in point-by-point comparison
measures of estradiol in either phase of the
menstrual cycle. An analysis of women who
differed approximately 15-fold in the total
amount of melatonin they chronically
secrete each night showed no associated dif-
ferences in blood levels of estradiol.
Most of the research to determine if
EMF exposure reduces melatonin has been
performed on rodents and other small ani-
mals. Contrary to popular opinion, this
research has not focused on the effects of
chronic exposure. Brainard et al. (4) charac-
terized 71 animal EMF/melatonin studies
performed since 1981. Exposure duration in
most (~70%) of the studies was 1 day or less,
and often it was 1 hr or less. It is important
to note, however, that melatonin (pineal,
plasma, or serum) suppression was reported
in approximately 40% of these acute expo-
sure studies, and that studies with longer
(≥ 30 days) exposures did not consistently
produce positive results. Field intensity in
the animal studies was typically less than 100
µT, with many studies using intensities in
the 30–50 µT range. Brainard et al. (4) also
describe 10 controlled EMF exposure studies
performed on large animals. At intensities
ranging from 0.6 to 100 µT, and at dura-
tions of minutes to months, EMF exposure
had no effect on melatonin or 6-OHMS in
large animals. Thus, although positive effects
have been reported at durations and intensi-
ties comparable to the present study, these
effects have been limited to small nocturnal
creatures whose reproductive and endocrine
function are intimately tied to the chronobio-
logical rhythms of melatonin.
The recent NIEHS EMF Working Group
report (14) concluded that only weak evidence
exists for EMF exposure effects on melatonin
in small animals, and no evidence exists that
it does so in large animals. In line with these
conclusions, we recently found that 4 consec-
utive nights of exposure to industrial-inten-
sity magnetic fields had no effect on
melatonin or 6-OHMS in humans (20), nor
did continuous exposure for 8 hr to very
strong (127.3 µT) ﬁelds (22). We have also
tested older women (40–60 years) in a sepa-
rate study (21) using the same EMF exposure
protocol described here, and again found no
effects on melatonin or 6-OHMS. Various
physiologically based explanations, other
than exposure duration or age, have been put
forth to account for effects being found in
small but not large animals (4).
Previous field studies of people exposed
to EMF while at home or at work do exam-
ine the effects of chronic exposure, and some
have reported suppression of melatonin
and/or 6-OHMS (e.g., 35–38). Thus, the
possibility exists that disturbances of the
melatonin rhythm may be related to as-yet
unknown aspects of the more complex mag-
netic ﬁelds found in the man-made environ-
ment. The evident weakness here is that
unknown elements have to be evoked to jus-
tify this possibility. There is also an inherent
lack of control over potentially confounding
variables in ﬁeld studies, which makes it dif-
ficult to reliably link the EMF exposure to
the reported positive effects. For example,
Arnetz and Berg (35) reported positive
effects. But this was based on a later analysis
of uncorrected urine samples stored for more
than 5 years after being collected from peo-
ple who sat before a computer terminal on
one day but not on another. EMF measure-
ments were not taken in the original study,
and EMF exposure is not now considered a
likely factor (15). Similarly, Pfluger and
Minder (36) reported reduced 6-OHMS in
train drivers exposed to 16.7-Hz magnetic
ﬁelds compared to a control group. The dri-
vers, however, worked shifts that advanced
each day by 15–60 min. This changed their
exposure to light and their daily melatonin
rhythms. Effects were not found in morning
urine, which represents the integrated noc-
turnal accumulation of melatonin during the
time in the 24-hr day when it is actively
being produced, but in early evening urine
collected when melatonin levels are rising at
variable rates across individuals. The chroni-
cally exposed (50 Hz, 1 µT) control group
showed no effects, and the authors indicate
their results may be due to light exposure. 
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Figure 5. Mean (± SE) estradiol levels are plotted
from 2100 hr to 0700 hr for the luteal group (n = 8)
initially exposed for 4 hr to bright (5,200 lx) light or
to dim (25 lx) light (study 3). Similar data are pre-
sented for the follicular group (n = 8) exposed to
the bright and dim light conditions. Unlike the pro-
found changes observed in melatonin (Figure 4),
no alterations in point-by-point matching mea-
sures of estradiol were found in either phase of
the menstrual cycle. 
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25 lx, lutealJuutilainen et al. (39) reported suppres-
sion of 6-OHMS in female garment workers
compared to office workers. They later
reported that 6-OHMS did not increase or
rebound over the nonworking weekends and
that no dose–response curve was present in
the workplace data (39). In an unpublished
study, Kaune et al. (37) found no relation-
ship to the magnetic ﬁelds measured by the
personal dosimeters worn by the women in
their study, and a weak suppressive effect of
magnetic ﬁelds in the bedroom on morning
6-OHMS. The generalizability of this effect
is unknown, however, as it was present in
summer and limited to women who used
medications known to reduce melatonin
(e.g., beta blockers). It has now been deter-
mined that the women in this cohort also
exhibit an alcohol-related, dose dependent
reduction in morning 6-OHMS levels (40).
Burch et al. (38) reported 6-OHMS sup-
pression in electric utility workers. This
effect was not related to intensity or cumula-
tive exposure in the workplace, however, but
to a derived measure of ﬁeld stability in the
home. In this same cohort of workers, 6-
OHMS levels are now reported to vary with
changes in the geomagnetic ﬁeld of the earth
as measured in Boulder, Colorado (41).
Field studies have important limitations that
must be taken into account when evaluating
reported claims for positive effects.
The search for a plausible biological
mechanism by which EMF exposure might
alter human physiology has been a central
research issue for some time (14,42). The
cascade of hormonal events postulated in the
melatonin hypothesis is often described as
providing such a mechanism (3), although
this postulated mechanism owes more to
rodent than to human physiology. A key
question here is how exposure to the mag-
netic ﬁeld comes to initiate this chain of hor-
monal events in the ﬁrst place. The synthesis
and release of melatonin from the pineal
gland is under the control of the suprachias-
matic nuclei (SCN) located in the hypothala-
mus, and the superior cervical ganglion
(SCG) located in the neck region (43). The
SCN are the pacemakers that generate the
endogenous circadian melatonin rhythm,
and the SCG is the main relay station for
melatonin release. The SCN are further
entrained to the 24-hr day by the eyes, which
relay light and dark signals via the retinohy-
pothalamic tract (RHT). Once produced by
the pineal, melatonin is released immediately
into the circulation, where it has a short half-
life in humans because more than 90% of it
is cleared from the circulation after a first
pass through the liver. For example, bolus
injection studies show that plasma melatonin
displays a bimodal decay pattern with a ﬁrst
distribution half-life of 2 min, and a second
metabolic half-life of 20 min (44). Thus, for
magnetic field exposure to suppress blood
levels of melatonin, it would have to exert a
“real-time” influence on cellular activity or
function somewhere in the region of the pro-
ducer (pineal gland), the rhythm generator
(SCN), the flow regulator (SCG), or the
entrainment pathway (RHT). 
By Faraday’s law, exposure to a time-
varying magnetic ﬁeld will induce an electric
ﬁeld inside a conducting body. If the induced
ﬁeld is of sufﬁcient intensity, it could provide
a plausible initiating mechanism to modulate
cellular activity or function. In recent com-
prehensive reviews (14,42), the value of 1
mV/m has been identified as the threshold
intensity required for documented electric
field-induced alterations in cellular activity.
Detailed dosimetric analyses with anatomi-
cally correct human models (45,46) indicate
that the present, industrial-strength (resultant
ﬂux density = 28.3 µT) magnetic ﬁeld expo-
sure conditions are capable of inducing peak
electric fields in human cortical brain areas
on the order of 1.8 mV/m. According to the
same dosimetric model, however, it would
require an exposure to 60-Hz magnetic ﬁelds
at an intensity almost 10 times higher than
that used here (~300 µT) to induce a 1
mV/m electric ﬁeld in the central region of
the human brain where the pineal and the
SCN are located. Calculations based on this
model also indicate that the present exposure
conditions would induce an electric ﬁeld of
only 0.1 mV/m at the retina, and a ﬁeld of
approximately 0.56 mV/m at the SCG in the
neck region. Thus, there appears to be little
biophysical support for the hypothesis that
melatonin may be suppressed in humans by
nocturnal exposure to power-frequency mag-
netic ﬁelds at the low ﬁeld intensities (≤ 0.3
µT) typically found in residences, or even at
the somewhat higher ﬁeld intensities (≤ 1.0
µT) characteristic of average exposure in the
electric utility workplace.
The physiological relevance of the small
changes in melatonin and/or 6-OHMS
observed in the above field studies is also
unknown because the typical nocturnal con-
centration of melatonin greatly exceeds the
amount needed for human melatonin recep-
tors to be activated. Even in EMF exposure
studies with seasonal breeders such as the
Djungarian hamster, where reproductive
function is exquisitely tuned to seasonal
changes in the duration of the nocturnal rise
in circulating blood levels of melatonin, the
typical reduction reported is less than 25%,
not nearly enough to trigger changes in
reproductive hormonal activity (15,47). 
In contrast, during exposure to bright light
at night, melatonin was suppressed in women
to a much greater degree (> 90%) than
reported to date in EMF exposure studies. To
our knowledge this is the ﬁrst published study
to simultaneously examine the effects of varia-
tion in LAN on melatonin and estradiol in
women. Although we found no relationship
between LAN and estradiol in either phase of
the menstrual cycle, two previous reports do
provide indirect evidence for a possible link
between LAN and breast cancer through the
melatonin hypothesis. Hahn (48) found that
breast cancer incidence rates were lower in
blind women (increased melatonin, less sensi-
tivity to LAN) compared to sighted women.
Tynes et al. (49) also reported that rates were
higher in a postmenopausal subsample of
female marine radio operators doing shift
work while at sea (less melatonin, greater
exposure to LAN). Thus, there may be cir-
cumstances under which long-term exposure
to LAN could be consequential in terms of
hormone levels and human health; however,
no epidemiological studies have directly
examined the relationship between LAN and
breast cancer. 
The three studies described here demon-
strate that circulating blood levels of mela-
tonin and estrogen are not altered in women
exposed at night to EMF at industrial inten-
sities, or when melatonin levels are pro-
foundly suppressed by LAN. Taken together,
our findings are consistent with a growing
body of evidence which generally suggests
that environmental EMF exposure has little
or no effect on the endocrine parameters
measured in this report. 
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